Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Throughput CETSA Identifies Small Molecule Modulators of ILT3 (LILRB4) with Functional Activity in Human iPSC-Derived Microglia for Alzheimer's Disease.

ACS medicinal chemistry letters·2026
Same author

HTS-Oracle v2: Prospective Ai-Guided Discovery and Experimental Validation of Small Molecule Modulators Across Multiple Targets.

Journal of chemical information and modeling·2026
Same author

From DNA-encoded library (DEL) screening to in vivo validation: LILRB4 (ILT3)-targeted small molecules reprograms myeloid immune suppression.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same author

AI-Enforced Ultra-Large Virtual Screening Discovers Potent CD28 Binders.

Journal of chemical information and modeling·2026
Same author

Peptides as programmable molecular scaffolds: from chemical synthesis and engineering to translational medicine.

RSC chemical biology·2026

Related Experiment Video

Updated: Jun 23, 2025

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
11:09

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Published on: August 1, 2018

10.7K

Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors.

Somaya A Abdel-Rahman1,2, Victor Ovchinnikov3, Moustafa T Gabr1

  • 1Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, New York 10065, United States.

ACS Medicinal Chemistry Letters
|June 19, 2024
PubMed
Summary

Researchers designed a novel cyclic peptide (P2) to inhibit T-cell immunoglobulin mucin-3 (TIM-3) interactions, offering a promising alternative to monoclonal antibodies for cancer immunotherapy.

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Related Experiment Videos

Last Updated: Jun 23, 2025

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
11:09

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Published on: August 1, 2018

10.7K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Area of Science:

  • Immunology
  • Biochemistry
  • Drug Discovery

Background:

  • T-cell immunoglobulin mucin-3 (TIM-3) blockade enhances cancer immunotherapy by overcoming immune suppression.
  • Current TIM-3 inhibitors, monoclonal antibodies (mAbs), have limitations including immunogenicity, poor tumor penetration, and high costs.

Purpose of the Study:

  • To rationally design and develop constrained peptides as potent inhibitors of TIM-3.
  • To evaluate the efficacy of designed peptides in blocking TIM-3 interactions and reversing immunosuppression.

Main Methods:

  • Structure-based in silico design of cyclic peptides targeting TIM-3, guided by X-ray cocrystal structures.
  • Surface plasmon resonance (SPR) for binding affinity determination (KD).
  • Cell-free and cell-based assays to assess inhibition of TIM-3 ligand interactions and reversal of T-cell-mediated immunosuppression.

Main Results:

  • A top cyclic peptide (P2) demonstrated strong binding to TIM-3 with a KD of 166.3 ± 12.1 nM.
  • P2 efficiently inhibited key TIM-3 interactions with its natural ligands at submicromolar concentrations.
  • P2 reversed immunosuppression in T-cell/cancer cell cocultures and exhibited favorable in vitro pharmacokinetic properties.

Conclusions:

  • Rational peptide design offers a viable alternative to mAbs for TIM-3 inhibition in cancer immunotherapy.
  • The cyclic peptide P2 shows significant potential as a therapeutic agent for immuno-oncology applications.
  • Further preclinical evaluation of P2 is warranted to assess its therapeutic efficacy in cancer models.